c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549

References

• Judd J, Borghaei H. Combining immunotherapy and chemotherapy for non-small cell lung cancer[J]. Thorac Surg Clin. 2020;30(2):199–206.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Xiao X, Saw PE, et al. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment[J]. Sci China Life Sci. 2020;63(2):180–205.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang J, Wu X, et al. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy[J]. Front Med. 2019;13(1):57–68.
   PubMed Web of Science ®Google Scholar
• Li K, Pan X, Bi Y, et al. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma[J]. Oncotarget. 2016;7(3):2496–2507.
   PubMedGoogle Scholar
• Kim KH, Kim H. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy[J]. ExpMolMed. 2017;49(3):e307.
   Google Scholar
• Liang H. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis[J]. Onco Targets Ther. 2020;13:2491–2510.
   PubMed Web of Science ®Google Scholar
• Zhuang PH, Xu L, Gao L, et al. Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma[J]. Onco Targets Ther. 2017;10:847–857.
   PubMed Web of Science ®Google Scholar
• Salgia R. MET in lung cancer: biomarker selection based on scientific rationale[J]. Mol Cancer Ther. 2017;16(4):555–565.
   PubMed Web of Science ®Google Scholar
• Miranda O, Farooqui M, Siegfried J. Status of agents targeting the HGF/c-Met axis in lung cancer[J]. Cancers (Basel). 2018;10(9):280.
   PubMed Web of Science ®Google Scholar
• Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes[J]. Oncogene. 2007;26(9):1276–1285.
   PubMed Web of Science ®Google Scholar
• Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors[J]. J Clin Invest. 2002;109(7):863–867.
   PubMed Web of Science ®Google Scholar
• Liu B, Liu ZZ, Zhou ML, et al. Development of c‑Met‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells[J]. Mol Med Rep. 2019;20(3):2823–2831.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Yamada T, Akeuchi S T, et al. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway[J]. Cancer Sci. 2017;108(7):1378–1385.
   PubMed Web of Science ®Google Scholar
• Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis[J]. Lung Cancer. 2019;133:96–102.
   PubMed Web of Science ®Google Scholar
• Congya Z, Dongyi P, Xiao S, et al. High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma[J]. Cancer Med. 2018;7(11):5525–5533.
   PubMed Web of Science ®Google Scholar
• Wu YL, Soo RA, Locatelli G, et al. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer. Cancer Treat Rev. 2017;61:70–81.
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–730.
   PubMed Web of Science ®Google Scholar
• Yin W, Cheng J, Tang Z, et al. MET amplification (MET/CEP7 Ratio ≥ 1.8) is an independent poor prognostic marker in patients with treatment-naive non-small-cell lung cancer. Clin Lung Cancer. 2021;22(4):e512–e518.
   PubMed Web of Science ®Google Scholar
• Yu F, Wang X, Shi H, et al. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Tumori. 2021;107(4):341–352.
   PubMed Web of Science ®Google Scholar
• Nai Y, Du L, Shen M, et al. TRAIL-R1-targeted CAR-T cells exhibit dual antitumor efficacy. Front Mol Biosci. 2021;8:756599.
   PubMed Web of Science ®Google Scholar
• Lin GQ, Zhang YM, Kang LQ, et al. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi. 2020;41(10):829–835.
   PubMedGoogle Scholar
• Xia L, Zheng Z, Liu JY, et al. Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res. 2021;9(6):707–722.
   PubMed Web of Science ®Google Scholar
• Shu R, Evtimov VJ, Hammett MV, et al. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Mol Ther Oncolytics. 2021;20:325–341.
   PubMed Web of Science ®Google Scholar
• Yu L, Li Z, Mei H, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunology. 2021;10(2):e1248.
   PubMed Web of Science ®Google Scholar
• Li P, Yang L, Li T, et al. The third generation anti-HER2 chimeric antigen receptor mouse T cells alone or together with anti-PD1 antibody inhibits the growth of mouse breast tumor cells expressing HER2 in vitro and in immune competent mice. Front Oncol. 2020;10:1143.
   PubMed Web of Science ®Google Scholar
• Kang L, Tang X, Zhang J, et al. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Exp Hematol Oncol. 2020;9(1):11.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zeng J, Liu T, et al. DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro. Cancer Manag Res. 2020;12:3247–3255.
   PubMed Web of Science ®Google Scholar
• Liu MJ, Mu J, Yuan T, et al. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi. 2021;42(2):140–145.
   PubMedGoogle Scholar
• He P, Tan Z, Wei Z, et al. Co-expressing LRP6 with anti-CD19 CAR-T cells for improved therapeutic effect against B-ALL. Front Oncol. 2020;10:1346. Published 2020 Sep 15.
   PubMed Web of Science ®Google Scholar
• Shen L, Li H, Bin S, et al. The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells. Oncol Rep. 2019;42(4):1549–1557.
   PubMed Web of Science ®Google Scholar
• Wang H, Ye X, Ju Y, et al. Minicircle DNA-Mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo [published correction appears in onco targets ther. 2020 Jun 17;13:5707]. Onco Targets Ther. 2020;13:3703–3716.
   PubMed Web of Science ®Google Scholar
• Samaha H, Pignata A, Fousek K, et al. A homing system targets therapeutic T cells to brain cancer[J]. Nature. 2018;561(7723):331–337.
   PubMed Web of Science ®Google Scholar
• Brudno JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management[J]. Blood Rev. 2019;34:45–55.
   PubMed Web of Science ®Google Scholar
• Wilkins O, Keeler AM, Flotte TR. CAR T-cell therapy: progress and prospects[J]. Hum Gene Ther Methods. 2017;28(2):61–66.
   PubMed Web of Science ®Google Scholar
• McLellan AD. Chimeric antigen receptor T cell persistence and memory cell formation[J]. Immunol Cell Biol. 2019;97(7):664–674.
   PubMed Web of Science ®Google Scholar
• Wang D, Aguilar B, Starr R, et al. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight. 2018;3(10):e99048.
   PubMed Web of Science ®Google Scholar
• Stock S, Hoffmann JM, Schubert ML, et al. Influence of retronectin-mediated T-cell activation on expansion and phenotype of CD19-specific chimeric antigen receptor T cells. Hum Gene Ther. 2018;29(10):1167–1182.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu Y, Xiang J, et al. Targeting Alpha-Fetoprotein (AFP)-MHC complex w.
   Google Scholar